PharmaSGP with strong revenues growth in 9M 2024 – revenues forecast for FY 2024 raised  Gräfelfing, November 14, 2024 – In the third quarter of 2024, the German OTC pharmaceutical company PharmaSGP Holding SE was able to continue the dynamic business development of the first half of the year, generating revenues of €88.6 million in the first nin [ … ]

CEO change at PharmaSGP Holding SE: Peter Gerckens succeeds Natalie Weigand as of January 1, 2025   Gräfelfing, November 05, 2024 - German OTC pharmaceutical company PharmaSGP Holding SE is announcing a change in the position of Chief Executive Officer (CEO). After more than seven years as CEO, Natalie Weigand informed the Supervisory Board today [ … ]

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.   PharmaSGP Holding SE has purchased 477,701 own sha [ … ]

PharmaSGP continues dynamic growth path in the first half of 2024 Gräfelfing, September 12, 2024 – The German OTC pharmaceutical company PharmaSGP Holding SE continued its dynamic growth path in the first half of 2024, achieving half-year revenues of €58.4 million based on preliminary, unaudited figures. This represents an increase of 17.4% compa [ … ]

PharmaSGP Holding SE: Annual General Meeting approves full distribution of the Group’s profit for 2023 following a successful business performance 89.74% of the share capital was represented; all agenda items were approved Shareholders approve increased dividend distribution of €1.36 per dividend-bearing share The appointment of Peter Gerckens  [ … ]

PharmaSGP Holding SE strengthens the Management Board to further accelerate growth PharmaSGP expands the Management Board as of July 1, 2024 with Peter Gerckens as Chief Commercial Officer (CCO), a newly created position Peter Gerckens will be responsible for international markets, sales and new businesses Gräfelfing, June 21, 2024 – German OTC p [ … ]

PharmaSGP continues dynamic business development with significant revenues growth in Q1 2024 Gräfelfing, May 14, 2024 – German OTC pharmaceutical company PharmaSGP Holding SE continued the positive business development of 2023 in the first quarter of 2024 and achieved an increase in revenues of 25.6% to €30.1 million (prior-year quarter: €24.0 mil [ … ]

PharmaSGP exceeds the € 100 million revenues mark in 2023 and plans further profitable growth in 2024 Gräfelfing, April 16, 2024 – German OTC pharmaceutical company PharmaSGP Holding SE continued the successful development of previous years in the 2023 financial year and exceeded the € 100 million revenues mark for the first time in the company's  [ … ]